Evaluation of Crisaborole 2% Versus Tacrolimus 0.1% Each Combined With Excimer Light in the Treatment of Stable Non-segmental Facial Vitiligo: a Prospective Randomized Controlled Study.

Inclusion Criteria: * Age ≥ 6 years old. * Both male and female patients. * Localized facial vitiligo involving less than 50% of the facial surface area. * Stable vitiligo defined by fulfillment of both of the following criteria simultaneously at screening: * Vitiligo Disease Activity (VIDA) score ≤ 0. * Vitiligo Signs of Activity Score (VSAS) = 0. * Ability and willingness to comply with treatment and follow-up visits Exclusion Criteria: * Patients younger than 6 years. * Segmental vitiligo. * Vitiligo universalis. * Pregnancy \& breastfeeding. * History of transplantation procedure for vitiligo within the past 6 months. * History of hypersensitivity to the study medication. * History of any skin bleaching treatment for vitiligo or other dermatoses at any point. * Any contraindication to excimer light therapy e.g., history of skin cancer, photosensitivity disorders. * Current history of systemic therapy or phototherapy. * Any topical treatment (such as topical steroids, calcineurin inhibitors, vitamin D analogs, JAK inhibitors, PDE4i) requires a washout period of 2 weeks before screening visit and through the final safety follow-up visit. * Ultraviolet light exposure, including UVB/UVA/PUVA delivered by booth/excimer laser, or tanning bed exposure, requires a washout period of 8 weeks before screening and through the final safety follow-up visit.